Hematological adverse events of sunitinib in treatment of advanced renal cell carcinoma
10.3760/cma.j.issn.1000-6702.2012.08.019
- VernacularTitle:舒尼替尼治疗晚期肾癌中血液学不良反应的诊治体会
- Author:
Xiaoyi HU
;
Guomin WANG
;
Jianming GUO
;
Zongming LIN
;
Lian SUN
;
Ming XU
;
Zhibing XU
;
Hang WANG
;
Ruiming RONG
;
Chen CANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,renal cell;
Malate sunitinib;
Drug toxicity;
Hematology
- From:
Chinese Journal of Urology
2012;33(8):627-630
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the hematological adverse events of sunitinib in treatment of advanced renal cell carcinoma.Methods Forty-four male patients and 18 female patients were included in this study.They were all with metastatic renal cell carcinoma and received sunitinib treatment at the dose of 50 mg daily in repeated 6 weeks cycle (4 weeks on and 2 weeks off).Toxicity was assessed every cycle with tumor assessments every 2 cycles via CT or PET-CT.Results Fifty patients (80.6％) had experienced treatment-related hematotoxicity,including leucocytopenia,anemia and thrombocytopenia.Severe hematological adverse events ( grade 3 -4 ) occured in 18 patients ( 29.0％ ) and slight events ( grade 1 - 2 ) in others (51.6％).Most of the hematological adverse events were manageable and reversible and treatment-changes (dose reduction,interruption) were necessary in severe cases.Almost half of the dose reduction (9/21,42.9％ ) were owing to hematotoxicity.Conclusions Sunitinib of 50 mg dose on schedule 4/2 is effective and well-tolerated in advanced renal carcinoma patients.Hematological adverse events are frequent in Chinese patients and can be controlled well.
